The objective of this report is to provide guidance in developing an appropriate analytical scope of testing for NPS...
Reports
NPS Alert: Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replace Eutylone in Drug Supply Typically Sold as “Ecstacy” or “Molly”
/ /
The objective of this announcement is to notify public health and safety, law enforcement, first responder, clinicians, medical examiners...
This report provides up-to-date information regarding the status of NPS opioid prevalence and positivity within the United States
This report provides up-to-date information regarding NPS stimulant & NPS hallucinogen prevalence and positivity within the United States.
This report provides up-to-date information regarding the status of NPS benzodiazepine prevalence and positivity within the US.
This report provides up-to-date information regarding the status of synthetic cannabinoid prevalence and positivity within the United States.
Ohio Governor Mike DeWine today signed Executive Order 2022-05D to suspend the normal rulemaking process to allow the State...
Kit Check's Hospital Pharmacy Operations Report survey is a road map forward—shedding light on the state of the industry...
The World Health Organization published the meeting report of the 44th Expert Committee on Drug Dependence (ECDD)
The purpose of this report is to provide up-to-date information regarding the drug supply in Philadelphia, Pennsylvania.
Trending Reports
-
Recommended Scope for NPS Testing in the United States: Q1 2022 May 12, 2022
-
NPS Alert: Synthetic Stimulant Market Rapidly Changing as N,N-Dimethylpentylone Replace Eutylone in Drug Supply Typically Sold as “Ecstacy” or “Molly” April 22, 2022
-
Trend Report: NPS Opioids in the US – Q1 2022 April 12, 2022
-
Trend Report: NPS Stimulants & Hallucinogens in the US – Q1 2022 April 12, 2022
-
Trend Report: NPS Benzodiazepines in the US – Q1 2022 April 12, 2022